Seguinoside F



Compound IDCDAMM02794
Common nameSeguinoside F
IUPAC name[5-[4,5-dihydroxy-6-(hydroxymethyl)-2-(4-hydroxyphenoxy)oxan-3-yl]oxy-3,4-dihydroxyoxolan-3-yl]methyl 4-hydroxy-3,5-dimethoxybenzoate
Molecular formulaC26H32O15

Experimental data

Retention time14.74
Adduct[M+NH4]+
Actual mz602.207
Theoretical mz602.208
Error1.53
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.1987

Identifiers and class information

Inchi keyHZFQJXUVAZJXLJ-DTJQOHLDNA-N
SmilesO=C(OCC1(O)COC(OC2C(O)C(O)C(OC2OC3=CC=C(O)C=C3)CO)C1O)C4=CC(OC)=C(O)C(OC)=C4
SuperclassPhenylpropanoids and polyketides
ClassTannins

Pharmacokinetic properties

Number of descriptor values(#stars)8
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)17
Number of reactive functional groups (#rtvFG)3
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)584.53
Computed dipole moment(dipole)3.422
Total solvent accessible surface area (SASA)891.179
Hydrophobic component of SASA (FOSA)363.662
Hydrophilic component of SASA (FISA)343.471
Pie component of the SASA (PISA)184.045
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1660.19
Number of hydrogen bond donors (donorHB)7
Number of hydrogen bond acceptors (accptHB)18.4
Free energy of solvation of dipole (dip^2/V)0.0070542
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0546263
Globularity descriptor (glob)0.760862
Predicted polarizability in cubic angstroms (QPpolrz)51.129
Predicted hexadecane/gas partition coefficient (QPlogPC16)19.21
Predicted octanol/gas partition coefficient (QPlogPoct)37.689
Predicted water/gas partition coefficient (QPlogPw)30.078
Predicted octanol/water partition coefficient (QPlogPo/w)-0.672
Predicted aqueous solubility (QPlogS)-3.352
Conformation-independent predicted aqueous solubility (CIQPlogS)-4.349
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-6.279
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)5.48
Predicted brain/blood partition coefficient (QPlogBB)-4.417
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)1.779
Predicted skin permeability, log Kp (QPlogKp)-5.569
PM3 calculated ionization potential (IP(ev))8.818
PM3 calculated electron affinity (EA(eV))0.526
Number of likely metabolic reactions (#metab)9
Prediction of binding to human serum albumin (QPlogKhsa)-1.13
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)0
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)227.265
Number of nitrogen and oxygen atoms (#NandO)15
Number of violations of Lipinski’s rule of five (RuleOfFive)3
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
O43570CA12Carbonic anhydrase XIIT16987SEA
P15692VEGFAVascular endothelial growth factor AT20761SEA
P05230FGF1Acidic fibroblast growth factorT18639SEA
P09038FGF2Basic fibroblast growth factorT31621SEA
P14151SELLLeukocyte adhesion molecule-1T60526SEA
P60568IL2Interleukin-2T61698SEA
Q9NUW8TDP1Tyrosyl-DNA phosphodiesterase 1T33492SwissTargetPrediction and SEA
P17931LGALS3Galectin-3T72038SEA
P14679TYRTyrosinaseT97035SEA
P09382LGALS1Galectin-1T09544SEA
Q9NZ08ERAP1Endoplasmic reticulum aminopeptidase 1T72849SEA
P05231IL6Interleukin-6T32578SEA
Q99417MYCBPMYCBP messenger RNAT37298SEA
P30837ALDH1B1Acetaldehyde dehydrogenaseT99641SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T16987DI0046Bacterial infection[ICD-11: 1A00-1C4Z]O43570CA12
T16987DI0372Seborrhoeic dermatitis[ICD-11: EA81]O43570CA12
T20761DI0095Colorectal cancer[ICD-11: 2B91]P15692VEGFA
T20761DI0365Retinopathy[ICD-11: 9B71]P15692VEGFA
T20761DI0430Vascular system developmental anomaly[ICD-11: LA90]P15692VEGFA
T18639DI0081Chronic arterial occlusive disease[ICD-11: BD4Z]P05230FGF1
T18639DI0102Coronary atherosclerosis[ICD-11: BA52]P05230FGF1
T31621DI0005Acne vulgaris[ICD-11: ED80]P09038FGF2
T60526DI0037Asthma[ICD-11: CA23]P14151SELL
T60526DI0088Circulatory system disease[ICD-11: BE2Z]P14151SELL
T61698DI0275Multiple sclerosis[ICD-11: 8A40]P60568IL2
T61698DI0361Renal cell carcinoma[ICD-11: 2C90]P60568IL2
T72038DI0190Hypertension[ICD-11: BA00-BA04]P17931LGALS3
T72038DI0199Idiopathic interstitial pneumonitis[ICD-11: CB03]P17931LGALS3
T72038DI0252Melanoma[ICD-11: 2C30]P17931LGALS3
T72038DI0302Non-alcoholic fatty liver disease[ICD-11: DB92]P17931LGALS3
T72038DI0351Psoriasis[ICD-11: EA90]P17931LGALS3
T97035DI0007Acquired hypermelanosis[ICD-11: ED60]P14679TYR
T97035DI0008Acquired hypomelanotic disorder[ICD-11: ED63]P14679TYR
T32578DI0028Anemia[ICD-11: 3A00-3A9Z]P05231IL6
T37298DI0235Liver cancer[ICD-11: 2C12]Q99417MYCBP
T99641DI0396Substance abuse[ICD-11: 6C40]P30837ALDH1B1

Copyright © 2025